Insider Buy: Vera Therapeutics - MarketScreener

Mar 3, 2023 · -- Beth C Seidenberg, Director, on March 01, 2023, executed a purchase for 23,478 shares in Vera Therapeutics for $170,047. Following the Form 4 filing with the SEC, …

$170047
OFF

Insider Buy: Vera Therapeutics - MarketScreener

1 week from now

Mar 3, 2023 · -- Beth C Seidenberg, Director, on March 01, 2023, executed a purchase for 23,478 shares in Vera Therapeutics for $170,047. Following the Form 4 filing with the SEC, …

marketscreener.com

$173192
OFF

Insider Buy: Vera Therapeutics - MarketScreener

1 week from now

-- Beth C Seidenberg, Director, on March 28, 2023, executed a purchase for 23,908 shares in Vera Therapeutics for $173,192. Following the Form 4 filing with the SEC, Seidenberg has …

marketscreener.com

$343485
OFF

Insider Buy: Vera Therapeutics - Ca.marketscreener.com

1 week from now

Mar 14, 2023 · -- Beth C Seidenberg, Director, on March 10, 2023, executed a purchase for 48,003 shares in Vera Therapeutics for $343,485. Following the Form 4 filing with the SEC, …

marketscreener.com

$31.00
OFF

Vera Therapeutics (VERA) Insider Trading Activity 2025 - MarketBeat

1 week from now

4 days ago · Which executives are buying and selling shares of Vera Therapeutics stock? View the latest VERA insider trading activity at MarketBeat. ... Buy: 161,290: $31.00: $4,999,990.00 …

marketbeat.com

$636915
OFF

Insider Buy: Vera Therapeutics -March 21, 2023 At 04:47 Pm

1 week from now

Mar 21, 2023 · -- Beth C Seidenberg, Director, on March 17, 2023, executed a purchase for 89,297 shares in Vera Therapeutics for $636,915. Following the Form 4 filing with the SEC, …

marketscreener.com

$753680
OFF

Vera Therapeutics, Inc. Stock - MarketScreener.com

1 week from now

Apr 30, 2016 · Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing Dec. 20: MT Certain Class A common stock of Vera Therapeutics, Inc. are subject …

marketscreener.com

$753680
OFF

Vera Therapeutics Insider Sold Shares Worth $753,680, According …

1 week from now

Dec 20, 2024 · -- Marshall Fordyce, Director, President and CEO, on December 18, 2024, sold 17,500 shares in Vera Therapeutics for $753,680. Following the Form 4 filing with the SEC, …

marketscreener.com

$753.68
OFF

Vera Therapeutics, Inc. - MarketScreener.com

1 week from now

3 days ago · Vera Therapeutics Insider verkaufte Aktien im Wert von $753.680, laut einer aktuellen SEC Einreichung 20.12. MT Vera Therapeutics, Inc. ernennt Jason S. Carter zum …

marketscreener.com

$359973
OFF

Insider Sell: Vera Therapeutics - Uk.marketscreener.com

1 week from now

Dec 14, 2022 · -- Joanne Curley, Chief Development Officer, on December 12, 2022, sold 19,711 shares in Vera Therapeutics for $359,973. Following the Form 4 filing with the SEC, Curley …

marketscreener.com

$75.00
OFF

Evercore ISI Sticks To Its Buy Rating For Vera Therapeutics (VERA)

1 week from now

3 days ago · Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $75.00. The company’s shares …

businessinsider.com

$753680
OFF

Vera Therapeutics Insider Sold Shares Worth

1 week from now

Dec 20, 2024 · -- Marshall Fordyce, Director, President and CEO, on December 18, 2024, sold 17,500 shares in Vera Therapeutics for $753,680. Following the Form 4 filing with the SEC, …

marketscreener.com

$56.00
OFF

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down Following …

1 week from now

2 days ago · Guggenheim increased their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th.

etfdailynews.com

$1304435
OFF

Vera Therapeutics Insider Sold Shares Worth $1,304,435, …

1 week from now

-- Joseph R Young, Senior Vice President, Finance, Chief Accounting Officer, on May 15, 2024, sold 30,837 shares in Vera Therapeutics for $1,304,435. Following the Form 4 filing with the …

marketscreener.com

$753.68
OFF

Vera Therapeutics Verwerft Wereldwijde Rechten Op Een Dubbele …

1 week from now

4 days ago · Vera Therapeutics Insider verkocht aandelen ter waarde van $753.680, volgens een recente SEC filing 20/12: MT Vera Therapeutics, Inc. Stelt Jason S. Carter aan als Chief Legal …

marketscreener.com

FAQs about Insider Buy: Vera Therapeutics - MarketScreener Coupon?

Did Vera Therapeutics insiders buy shares?

While Vera Therapeutics insiders bought shares during the last year, they didn't sell. They paid about US$8.92 on average. It is certainly positive to see that insiders have invested their own money in the company. However, we do note that they were buying at significantly lower prices than today's share price. ...

Who owns Vera Therapeutics?

Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Vera Therapeutics in the second quarter worth $135,000. ...

How do you know if Vera Therapeutics is aligned with other shareholders?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Based on our data, Vera Therapeutics insiders have about 0.6% of the stock, worth approximately US$4.7m. ...

Is Vera Therapeutics a good stock to buy?

Of course Vera Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. ...

Does Mirae own Vera Therapeutics?

Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares in the last quarter. ...

Who are insiders?

So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions. ...